Augmented Reality
blood flow speeds
millions of surgeries
Help save more lives with an FDA Class I Augmented Reality Surgical Camera
300 million surgeries / year and good blood flow is a key to recovery
Current measurement tools originated in the ‘60s and require contact or injection of a contrast dye.
$4M
100+
shareholders
FDA
Class I
WORLD CLASS
vision & robotics
engineering
IP
patents and
trade secrets
Featured in ...
OVERVIEW
Future of assessing circulation in surgeries
VUFLOW is a unique non-contact, real-time system to help surgeons assess blood flow speeds (left image) in potentially hundreds of millions of major surgeries, where some form of revascularization may occur.
VUFLOW’s latest imaging head unit (right image) was tested with optional robotics upgrade (KUKA) that is targeted for availability in 2022.
point-n-image
to know-the-flow
VUFLOW imaging system is a mobile laboratory measurement instrument for fluid flow.
It operates 20 cm (8 inches) from the subject. And can measure speeds faster than 30 cm/s.
(current product shown)
VUFLOW R
Computer vision and robotics engineers and clinicians explore the latest medical robot arm and imaging head unit in a design facility.
VUFLOW R aims to provide surgeons with finger tip guidance that can record the path and automatically return to park or to the subject to save valuable time between measurements.
(optional robotics upgrade in 2022)
color speed map
speed graph
intuitive & informative
(left)
Easily visualize flow speeds as color map across an organ’s surface
(right)
Position the circle over an area of interest to image average flow speeds over time
growing market
Over 300M surgeries / year are performed.
The burgeoning blood flow measurement market has exceeded $500M / year.
Cutting and attaching blood vessels occurs in many types of surgeries. Ending with good blood is key because it sustains organs and tissue with O2 and nutrients and removes CO2 and byproducts.
Scinovia is entering this growing market with VUFLOW, a non-contact, quantitative alternative for current users of contrast dye and ultrasound probes in over 500K cases / year.
THE PROBLEM
1) A key challenge surgeons face is knowing if a procedure has poor blood flow
20%
of bypass grafts were below 50% of targeted flow.
Assessing speeds with flow probes provided opportunity to correct during surgery or plan post-operative interventions.
14%
of breast reconstructions have reoperations due to tissue death.
Assessing with ICG glow dye reduced reoperation to below 7%.
2) Current methods (published in 1962) require contact, which have limitations
OUR SOLUTION
KNOW-THE-FLOW IN
REAL-TIME WITH VUFLOW
Probe and Dye tools can often predict cases that will end with poor flow or tissue death (necrosis).
Poor outcomes can result in longer recovery for people, costly complications, re-admissions, re-operations, or death.
We designed VUFLOW to be faster and easier to use than probes or dye because it is non-contact, non-contrast injection.
Simply point-n-image to visualize blood flow speeds.
BUSINESS MODEL
Pay-per-use convertible to a multi-year Software as a Service subscription agreement
Sell to current users of probes and dyes: Displace or complement existing modalities
SNAPSHOT
7 units
$4M and 7 years of R&D produced our technological advantage
REV target 2022
Partners in contract manufacturing and service support for US and Europe
world-class team
Led by top surgeon innovators and experts in compute vision software
IP
2 patents and 2 applications, plus trade secret algorithms
Updates
